A new Neurology cohort study ↗ in 73,644 adults with migraine receiving preventive treatment shows that calcitonin gene-related peptide inhibitors (CGRPi), the class that includes Aimovig (erenumab), Vyepti (eptinezumab), Ajovy (fremanezumab), Emgality (galcanezumab), atogepant, and rimegepant, reduce the risk of incident glaucoma compared with other migraine preventive medications. Hazard ratio 0.75 (95% CI 0.61-0.92) across the full CGRPi cohort over 3 years of follow-up, with the protective effect concentrated in the monoclonal-antibody subclass.
The methodology. Multinational retrospective cohort, propensity-score matched 1:1, drawing from migraine patients who received preventive medication between 2018 and 2024. CGRPi group included six approved agents. Non-CGRPi comparator group included ten older preventives: valproate, topiramate, flunarizine, candesartan, lisinopril, metoprolol, propranolol, nadolol, amitriptyline, and venlafaxine. Crossovers were not allowed; the non-CGRPi group consisted of patients who had never used CGRPi. Outcome ascertainment used Cox proportional hazards modeling. Class II evidence per AAN classification.
The headline result. Compared with non-CGRPi users, CGRPi users had a 25% lower risk of glaucoma over three years (HR 0.75, CI 0.61-0.92). The effect persisted in subgroup analyses against specific comparator drugs: HR 0.73 versus topiramate, 0.54 versus valproate, 0.49 versus lisinopril, 0.69 versus amitriptyline, 0.68 versus venlafaxine. The effect was preserved in older adults, women, chronic migraine patients, and migraine-without-aura patients. Within the CGRPi class, only the monoclonal antibody subclass (erenumab, eptinezumab, fremanezumab, galcanezumab) showed the reduced risk against non-CGRPi users (HR 0.77, CI 0.61-0.98). The small-molecule gepants (atogepant, rimegepant) did not show a separately significant effect, possibly because of smaller subgroup sample size.
What this changes for the migraine treatment landscape. Migraine has been linked to elevated glaucoma risk in epidemiological literature for two decades. The biology has been unclear: shared neurovascular dysfunction, vasoconstriction during migraine attacks, or possibly trigeminal-pathway involvement that intersects with intraocular dynamics. The new cohort suggests that CGRP-pathway antagonism, the mechanism that underlies CGRPi clinical efficacy in migraine prevention, has a downstream effect on glaucoma risk that other preventive mechanisms do not. The protective effect is meaningful in absolute terms: at the cohort's baseline glaucoma incidence rate, a 25% relative risk reduction translates to roughly a few cases per 1,000 patient-years prevented.
The mechanism context. CGRP itself is a vasoactive neuropeptide released from sensory neurons; its receptor is expressed across the cardiovascular system, the gastrointestinal tract, and the eye. In ocular tissue, CGRP modulates intraocular pressure regulation through indirect effects on aqueous humor dynamics. Blocking CGRP signaling pharmacologically may shift intraocular pressure homeostasis in ways that reduce glaucoma risk over time. The mechanism remains hypothesis-stage; the cohort study establishes the association, not the cause.
Why a peptide-news section is covering CGRP migraine drugs. CGRP is a peptide; CGRP receptor antagonists and CGRP-targeting monoclonal antibodies are peptide-binding therapeutics that the platform's design space directly engages. The CALCR/RAMP target page ↗ on peptidemodel hosts the calcitonin-receptor superfamily that includes CGRP, with cards like alpha-CGRP (8-37) ↗ covering receptor-binding peptide fragments directly. As the CGRP migraine drug class expands its evidence base into glaucoma protection alongside its established migraine-prevention indication, the platform's design relevance for CGRP-pathway therapeutics widens.
What this is not. A randomized trial. The cohort is retrospective, propensity-score-matched, and Class II evidence rather than Class I. The 25% relative risk reduction is meaningful but the absolute incidence depends on baseline patient characteristics, and the result does not establish CGRPi as a glaucoma-prevention therapy. What it does is extend the secondary-effects map for the CGRP migraine drug class, similar to the way the GLP-1 secondary-effects literature has expanded ↗ into kidney, retinal, cognitive, and behavioral domains over the past two years.
The pattern matters. Two peptide-targeted drug classes (GLP-1 and CGRP) are simultaneously producing surprising secondary-effects literature in 2026, both expanding well beyond their original on-label indications. The unifying theme is that peptide receptors with broad tissue distribution produce broad downstream effects when modulated chronically. The GLP-1 receptor's reach is now quantified across the umbrella review's 464 outcomes. The CGRP receptor's reach is just starting to get the same treatment.